TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) stock surged by 1.83% during current trading. TFF Pharmaceuticals, Inc. is a clinical-stage pharmaceutical business specializing in the development and commercialization of novel therapeutic treatments based on its unique Thin Film Freezing (TFF) technology platform.
TFFP stock’ Recent Past Development
TFF Pharmaceuticals has announced the release of a research paper outlining AUG-3387’s promising preclinical findings. It’s a monoclonal antibody (mAb) therapy for the cure of SARS-CoV-2 infection that the two firms are working on together. “AUG-3387, a Human-Derived Monoclonal Antibody Neutralizes SARS-CoV-2 Variants and Reduces Viral Load from Therapeutic Treatment of Hamsters In Vivo,” was the title under which the findings were being published online through the bioRxiv preprint service.
TFF Pharmaceuticals’ unique Thin Film Freezing technique was used to create the AUG-3387 mAb as a dry powder. The Thin Film Freezing technique was acquired in order to allow direct administration to the lungs, eliminating the requirement for intravenous infusion, which is necessary for existing COVID-19 antibody treatments. Augmenta Bioworks created the SingleCyte platform, which was used to isolate AUG-3387. Using AI-driven single-cell imaging and retrieval technologies, SingleCyte assesses human immunity quickly to find antigen-specific antibodies.
Infected hamsters were given the dry powder formulation of AUG-3387, which showed a dose-dependent decrease in viral load. It happened when the mAb treatment was started 24 hours after the SARS-CoV-2 infection. The previous mAbs that have obtained FDA Emergency Use Authorization for COVID-19 therapy have only shown effectiveness in the hamster model when given preventively 24 hours before infection with SARS-CoV-2. This research is also the first to show that inhaled administration of a dry powder monoclonal antibody therapy for COVID-19 illness may successfully reduce viral load. The findings imply that AUG-3387 might enhance already authorized COVID-19 antibody therapies by allowing for at-home administration, direct delivery to the lungs, and global expansion without the need for cold-chain storage.
AUG-3387 exhibited binding ability against the Alpha, Beta, Delta, Gamma, Kappa, Lambda, and Mu forms of SARS-CoV-2 in addition to its in vivo efficacy. Because AUG-3387 binds to all SARS-CoV-2 strains tested, it appears to address a highly conserved area of the virus, enabling it to stay effective despite the development of new variant strains.